Current status of non-transfusional haemostatic agents.
Cattaneo
M
M
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Ospedale Maggiore, Milan, Italy. marco.cattaneo@unimi.it
Mannucci
P M
PM
D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000150:complications / Q000151:congenital; D016063:Blood Loss, Surgical / Q000517:prevention & control; D006348:Cardiac Surgical Procedures; D000075202:Contraindications; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000209:etiology; D006490:Hemostatics / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D006801:Humans; D012449:Safety; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D014511:Uremia / Q000150:complications
D000933:Antifibrinolytic Agents; D004966:Estrogens, Conjugated (USP); D006490:Hemostatics; D014148:Tranexamic Acid; D007611:Aprotinin; D003894:Deamino Arginine Vasopressin; D015119:Aminocaproic Acid